Robert Balk to Cost-Benefit Analysis
This is a "connection" page, showing publications Robert Balk has written about Cost-Benefit Analysis.
Connection Strength
0.182
-
Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest. 2017 Jan; 151(1):23-33.
Score: 0.133
-
Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med. 2015 Mar; 53(4):583-92.
Score: 0.030
-
Noninvasive respiratory care unit. A cost effective solution for the future. Chest. 1988 Feb; 93(2):390-4.
Score: 0.018